Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€56.50

€56.50

-0.910%
-0.5
-0.910%
€62.32
 
07.10.25 / Tradegate WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Stock / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

Protagonist Therapeutics Inc Stock

Protagonist Therapeutics Inc shows a slight decrease today, losing -€0.500 (-0.910%) compared to yesterday.
The stock is one of the favorites of our community with 25 Buy predictions and 1 Sell predictions.
With a target price of 62 € there is a slightly positive potential of 9.73% for Protagonist Therapeutics Inc compared to the current price of 56.5 €.
So far the community has only identified positive things for Protagonist Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Protagonist Therapeutics Inc in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Prediction Buy
Perf. (%) -
Target price 68.808
Change
Ends at 08.10.26

Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.60%
Target price 67.480
Change
Ends at 17.09.26

Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.60%
Target price 60.732
Change
Ends at 17.09.26

Protagonist Therapeutics (NASDAQ:PTGX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $72.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Show more

News

Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist (PTGX) Q2 Revenue Falls 26%

Protagonist Therapeutics (NASDAQ:PTGX), a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025